RECURRENT HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for RECURRENT HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for RECURRENT HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to rally immune system against tough lymphomas
Disease control Recruiting nowThis study is testing a combination of two drugs, epcoritamab and ibrutinib, for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or stopped responding to previous treatments. The goal is to find a safe and effective dose. One drug helps the body's own immune…
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New bridge to a cancer cure: drug combo aims to get more patients to Life-Saving CAR-T
Disease control Recruiting nowThis study is testing a two-drug combination (golcadomide and rituximab) as a 'bridging therapy' for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to control the cancer and improve patients' health so they can qualify fo…
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma that returns
Disease control Recruiting nowThis study is testing a new treatment sequence for adults whose aggressive large B-cell lymphoma has come back or didn't respond to initial therapy. Participants first receive two targeted drugs (tafasitamab and lenalidomide), followed by a stronger chemotherapy regimen. The main…
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New immune therapy trial aims to control Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether adding a new immune-boosting drug called epcoritamab to standard chemotherapy and a stem cell transplant can better control aggressive large B-cell lymphoma that has returned or not responded to prior treatment. It will involve about 25 adults whose …
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New 5-Drug attack on Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a combination of five medications (called ViPOR) for people with aggressive types of B-cell lymphoma that have returned after treatment or did not respond to prior therapy. The goal is to see if this drug combination can effectively control the cancer and le…
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC